PRILOCARD 1.25 MG TABLETS FOR DOGS

Land: Irland

Sprog: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Aktiv bestanddel:

RAMIPRIL

Tilgængelig fra:

aniMedica GmbH

ATC-kode:

QC09AA05

INN (International Name):

RAMIPRIL

Dosering:

1.25 Milligram

Lægemiddelform:

Tablets

Recept type:

POM

Terapeutisk gruppe:

Canine

Terapeutisk område:

Ramipril

Terapeutiske indikationer:

Cardiovascular

Autorisation status:

Authorised

Autorisation dato:

2012-07-13

Produktets egenskaber

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Prilocard 1.25 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance:
Ramipril 1.25 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets.
White round biconvex tablets, imprinted with ‘B’ on one side of
the tablet and ‘48’ on the other.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For treatment of congestive heart failure (equivalent to New York
Heart Association [NYHA] classes II,
III and IV)
caused by valvular
insufficiency due to endocardiosis or
cardiomyopathy.
The preparation may if
applicable be
administered concomitantly with furosemide (diuretic) and/or the
cardiac glycosides digoxin or methyl digoxin.
In patients treated concomitantly with ramipril and furosemide, the
diuretic dose may be reduced to achieve the same
diuretic effect as in treatment with furosemide alone.
4.3 CONTRAINDICATIONS
Do not
use in haemodynamically-related stenoses (e.g.
aortic stenosis,
mitral
stenosis)
nor
in cases of
obstructive
hypertrophic cardiomyopathy.
Do not use in cases of hypersensitivity to the active substance,
ACE-inhibitors or to any of the excipient(s).
See Section 4.7 for use in Pregnancy and Lactation
Class
Clinical symptoms
II
Fatigue, dyspnoea, cough etc. seen in normal activity.
Ascites may occur at this stage.
III
Comfortable at rest, but capacity for activity minimal.
IV
Incapable of any activity.
Clinical symptoms of disablement occur even at rest.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___